Journal of Antimicrobial Chemotherapy · 2018 · 29 citations · 26 references
MedicinePharmacologyPsychiatryNeuropsychiatryPharmacogeneticsPsychopharmacologyAntipsychotic PharmacologyAntiretroviral TherapyDrug Transporter GeneticsHuman Immunodeficiency Virus PharmacotherapyNeuropsychiatric GeneticsReceptor PolymorphismsAllelic DiscriminationAntiretroviral ResponseDisease Severity IndexLogistic RegressionNeuropsychiatric EffectsPharmacodynamics Of Antiretroviral TherapySerotonin Transporter PolymorphismSeverity Index Measurement
BACKGROUND: Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (Ctrough) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2), which is involved in monoamine clearance in the CNS and is inhibited by dolutegravir, might be associated with NPs. METHODS: A cross-sectional cohort of HIV-positive patients treated with a dolutegravir-containing regimen underwent determination of allelic discrimination for SLC22A2 808 C → A polymorphism and dolutegravir Ctrough. The Symptom Checklist-90-R [investigating 10 psychiatric dimensions and reporting a general severity index (GSI)], a self-reported questionnaire and the Mini-International Neuropsychiatric Interview were offered to investigate current NPs. The effects of dolutegravir Ctrough and the SLC22A2 gene variant on NPs were explored by multivariable logistic regression. RESULTS: A cohort of 203 patients was analysed: 71.4% were male, with median age 51 years and 11 years of ART exposure. Median time on dolutegravir was 18 months. Dolutegravir was associated with different antiretroviral combinations (mainly lamivudine, 38.9%, and abacavir/lamivudine, 35.5%). SLC22A2 CA genotype was independently associated with an abnormal GSI [adjusted OR (aOR) 2.43; P = 0.072], anxiety (aOR 2.61; P = 0.044), hostility (aOR 3.76; P = 0.012) and with moderate to severe headache (aOR 5.55; P = 0.037), and dolutegravir Ctrough was associated with hostility (fourth versus first quartile aOR 6.70; P = 0.007) and psychoticism (fourth versus first quartile aOR 19.01; P = 0.008). Other NPs were not associated with SLC22A2 polymorphism or dolutegravir Ctrough. CONCLUSIONS: A variant of the OCT2-encoding gene, in addition to or in synergy with higher dolutegravir Ctrough, is associated with a set of NPs observed during dolutegravir therapy.
26
An atlas of genetic influences on human blood metabolites
So–Youn Shin, Eric B. Fauman, Ann-Kristin Petersen et al. · Nature Genetics · 2014 · 1.6K citations · Full text
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Sharon Walmsley, Antonio Antela, Nathan Clumeck et al. · New England Journal of Medicine · 2013 · 878 citations · Full text
Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 329 citations · Full text